Back
Regeneron Pharmaceuticals 10K Form
Sell
39
REGN
Regeneron Pharmaceuticals
Last Price:
737.85
Seasonality Move:
14.6%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-02 | 10Q | REGN/Regeneron Pharmaceuticals Quarterly |
| 2023-11-02 | 10Q | REGN/Regeneron Pharmaceuticals Quarterly |
| 2023-08-03 | 10Q | REGN/Regeneron Pharmaceuticals Quarterly |
| 2023-05-04 | 10Q | REGN/Regeneron Pharmaceuticals Quarterly |
| 2022-11-03 | 10Q | REGN/Regeneron Pharmaceuticals Quarterly |
| 2022-08-03 | 10Q | REGN/Regeneron Pharmaceuticals Quarterly |
Receive REGN News And Ratings
See the #1 stock for the next 7 days that we like better than REGN
REGN Financial Statistics
Sales & Book Value
| Annual Sales: | $13.12B |
|---|---|
| Cash Flow: | $1.05B |
| Price / Cash Flow: | 25.59 |
| Annual Sales: | $266.32 |
| Price / Book: | 2.77 |
Profitability
| EPS (TTM): | 40.41000 |
|---|---|
| Net Income (TTM): | $4.65B |
| Gross Margin: | $11.3B |
| Return on Equity: | 17.19% |
| Return on Assets: | 13.44% |
Regeneron Pharmaceuticals Earnings Forecast
Key Regeneron Pharmaceuticals Financial Ratios
- The Gross Profit Margin over the past 34 years for REGN is 86.16%.
- The Selling, General & Administrative Expenses for REGN have been equal to 20.06% of Gross Profit Margin.
- The Research & Development expenses have been 33.84% of Revenue.
- The Interest Expense is 1.85% of Operating Income.
- The Net Earning history of REGN is 30.14% of Total Revenues.
- Per Share Earnings over the last 34 years have been positive in 18 years.
Regeneron Pharmaceuticals Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | S&P500 |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | REGN |
| CUSIP: | 75886F |
| Website: | regeneron.com |
Debt
| Debt-to-Equity Ratio: | 0.07 |
|---|---|
| Current Ratio: | 5.28 |
| Quick Ratio: | 4.34 |
Price-to-Earnings
| Trailing P/E Ratio: | 21.23 |
|---|---|
| Forward P/E Ratio: | 16.29 |
REGN Technical Analysis vs Fundamental Analysis
Sell
39
Regeneron Pharmaceuticals (REGN)
is a Sell
Is Regeneron Pharmaceuticals a Buy or a Sell?
-
Regeneron Pharmaceuticals stock is rated a Sell
The current Regeneron Pharmaceuticals [REGN] share price is $738.00. The Score for REGN is 39, which is 22% below its historic median score of 50, and infers higher risk than normal.